

Anique Ducharme

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7986097/publications.pdf>

Version: 2024-02-01

160
papers

10,419
citations

50276

46
h-index

33894

99
g-index

168
all docs

168
docs citations

168
times ranked

10440
citing authors

#	ARTICLE	IF	CITATIONS
1	The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic. <i>European Heart Journal</i> , 2022, 43, 2603-2618.	2.2	27
2	Right ventricular function and its coupling to pulmonary circulation predicts exercise tolerance in systolic heart failure. <i>ESC Heart Failure</i> , 2022, 9, 450-464.	3.1	16
3	Atrial Electrical Remodeling in Mice With Cardiac-Specific Overexpression of Angiotensin II Type 1 Receptor. <i>Journal of the American Heart Association</i> , 2022, 11, e023974.	3.7	8
4	Severe myocarditis after SARS-CoV-2 vaccination in a 49-year-old woman. <i>Cmaj</i> , 2022, 194, E581-E584.	2.0	2
5	Initial clinical experience with VersaCross transseptal system for transcatheter mitral valve repair. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1230-1234.	1.7	10
6	Long-Chain Acylcarnitines and Monounsaturated Fatty Acids Discriminate Heart Failure Patients According to Pulmonary Hypertension Status. <i>Metabolites</i> , 2021, 11, 196.	2.9	5
7	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 531-546.	1.7	170
8	Transition of CRT clinic to telemedicine during the COVID-19 pandemic: A missed opportunity to optimized patients with heart failure with reduced ejection fraction?. <i>IJC Heart and Vasculature</i> , 2021, 34, 100820.	1.1	0
9	Optimizing Timing of Valve Intervention in Patients With Asymptomatic Severe Valvular Heart Disease. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1041-1053.	1.7	2
10	Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1629-1634.	1.7	45
11	Characteristics of Clinicians Are Associated With Their Beliefs About ICD Deactivation: Insight From the DECIDE-HF Study. <i>CJC Open</i> , 2021, 3, 994-1001.	1.5	1
12	Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. <i>Lancet</i> , 2021, 398, 991-1001.	13.7	218
13	Care Gaps in Adherence to Heart Failure Guidelines. <i>JACC: Heart Failure</i> , 2020, 8, 725-738.	4.1	55
14	Optimizing Access to Heart Failure Care in Canada During the COVID-19 Pandemic. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1148-1151.	1.7	19
15	Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care. <i>Canadian Journal of Cardiology</i> , 2020, 36, 335-356.	1.7	33
16	The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. <i>CJC Open</i> , 2020, 2, 151-160.	1.5	10
17	Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 322-334.	1.7	68
18	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 159-169.	1.7	89

#	ARTICLE	IF	CITATIONS
19	The Evolution of Transcatheter Therapies for Mitral Valve Disease: From Mitral Valvuloplasty to Transcatheter Mitral Valve Replacement. Canadian Journal of Cardiology, 2020, , .	1.7	7
20	Targeted Temperature Management After Cardiac Arrest: The Montreal Heart Institute Experience. CJC Open, 2019, 1, 238-244.	1.5	0
21	Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). American Heart Journal, 2019, 214, 18-27.	2.7	41
22	GDF-15 IS ASSOCIATED WITH FUNCTIONAL CAPACITY & VENTRICULAR DYSFUNCTION IN PATIENTS WITH MODERATE TO SEVERE AORTIC STENOSIS & PRESERVED EJECTION FRACTION. Journal of the American College of Cardiology, 2019, 73, 1962.	2.8	0
23	Current Review of Implantable Cardioverter Defibrillator Use in Patients With Left Ventricular Assist Device. Current Heart Failure Reports, 2019, 16, 229-239.	3.3	10
24	The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the <scp>BROâ€HF</scp> retrospective cohort study. ESC Heart Failure, 2019, 6, 27-36.	3.1	30
25	Association of recreational drug consumption, cardiac toxicity and heart transplantation. Canadian Journal of Surgery, 2019, 62, 356-357.	1.2	0
26	Pregnancy after heart transplantation: a well-thought-out decision? The Quebec provincial experience - a multi-centre cohort study. Transplant International, 2018, 31, 977-987.	1.6	25
27	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. International Journal of Cardiology, 2018, 266, 187-192.	1.7	27
28	A prospective study of the impact of <i>AGTR1</i> A1166C on the effects of candesartan in patients with heart failure. Pharmacogenomics, 2018, 19, 599-612.	1.3	10
29	Temporal Changes on the Risks and Complications of Posttransplantation Diabetes Mellitus Following Cardiac Transplantation. Journal of Transplantation, 2018, 2018, 1-11.	0.5	3
30	Setting Up a Heart Failure Program in 2018: Moving Towards New Paradigm(s). Current Heart Failure Reports, 2018, 15, 357-367.	3.3	3
31	Aortic regurgitation in patients with a left ventricular assist device: A contemporary review. Journal of Heart and Lung Transplantation, 2018, 37, 1289-1297.	0.6	51
32	Left Ventricular Outflow Tract Obstruction Following Mitral Valve Replacement: Challenges for Transcatheter Mitral Valve Therapy. Structural Heart, 2018, 2, 372-379.	0.6	7
33	A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial. American Heart Journal, 2018, 204, 190-195.	2.7	7
34	Multicenter evaluation of a national organ sharing policy for highly sensitized patients listed for heart transplantation in Canada. Journal of Heart and Lung Transplantation, 2017, 36, 491-498.	0.6	24
35	Collectively Operated Fellow-Initiated Research as a Novel Teaching Model to Bolster Interest and Increase Proficiency in Academic Research. Canadian Journal of Cardiology, 2017, 33, 685-687.	1.7	6
36	Impact of Left Ventricular vs Biventricular Pacing on Reverse Remodelling: Insights From the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) Trial. Canadian Journal of Cardiology, 2017, 33, 1274-1282.	1.7	11

#	ARTICLE	IF	CITATIONS
37	The Need for Heart Failure Advocacy in Canada. Canadian Journal of Cardiology, 2017, 33, 1450-1454.	1.7	25
38	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology, 2017, 33, 1342-1433.	1.7	503
39	Circulating acylcarnitine profile in human heart failure: a surrogate of fatty acid metabolic dysregulation in mitochondria and beyond. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H768-H781.	3.2	95
40	Do Heart Failure Clinics Have to Reinvent Themselves to Remain Germane?. Canadian Journal of Cardiology, 2017, 33, 1212-1214.	1.7	6
41	Barriers to Goals of Care Discussions With Patients Who Have Advanced Heart Failure: Results of a Multicenter Survey of Hospital-Based Cardiology Clinicians. Journal of Cardiac Failure, 2017, 23, 786-793.	1.7	33
42	Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years Following Heart Transplantation. JACC: Heart Failure, 2017, 5, 891-901.	4.1	35
43	Preoperative Optimization of the Heart Failure Patient Undergoing Cardiac Surgery. Canadian Journal of Cardiology, 2017, 33, 72-79.	1.7	26
44	Clinical outcomes and economic impact of transcatheter mitral leaflet repair in heart failure patients. Journal of Medical Economics, 2017, 20, 82-90.	2.1	20
45	Experience with the SynCardia total artificial heart in a Canadian centre. Canadian Journal of Surgery, 2017, 60, 375-379.	1.2	14
46	Changes in patient characteristics following cardiac transplantation: the Montreal Heart Institute experience. Canadian Journal of Surgery, 2017, 60, 305-310.	1.2	2
47	Impact of left ventricular function on clinical outcomes of functional mitral regurgitation patients undergoing transcatheter mitral valve repair. Catheterization and Cardiovascular Interventions, 2016, 88, 1124-1133.	1.7	16
48	Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. Seminars in Thoracic and Cardiovascular Surgery, 2016, 28, 320-328.	0.6	26
49	The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. Canadian Journal of Cardiology, 2016, 32, 296-310.	1.7	86
50	Markers and Correlates of Right Ventricular Function with Computed Tomography, Echocardiography, and Magnetic Resonance. , 2016, , 1183-1219.		0
51	Decreased circulating and neutrophil mediated VEGF-A165 release in stable long-term cardiac transplant recipients. Vascular Cell, 2015, 7, 4.	0.2	2
52	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. European Journal of Heart Failure, 2015, 17, 1066-1074.	7.1	85
53	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. Canadian Journal of Cardiology, 2015, 31, 3-16.	1.7	96
54	Late Infection of an Atrial Septal Defect Closure Device: A Possible Complication. Canadian Journal of Cardiology, 2015, 31, 1204.e9-1204.e11.	1.7	4

#	ARTICLE	IF	CITATIONS
55	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 487-496.	4.1	204
56	The Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1421-1426.	1.7	23
57	Very Low Ventricular Pacing Rates Can Be Achieved Safely in a Heterogeneous Pacemaker Population and Provide Clinical Benefits: The CANadian Multi-Centre Randomised Study of Spontaneous AtrioVentricular Conduction pReservation (CAN-SAVE R) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	12
58	Markers and Correlates of Right Ventricular Function with Computed Tomography, Echocardiography, and Magnetic Resonance. , 2015, , 1-38.		0
59	Heart Failure With Anemia. <i>Circulation: Heart Failure</i> , 2014, 7, 773-781.	3.9	43
60	The Epidemic of Heart Failure: A Lucid Approach to Stemming the Rising Tide. <i>Canadian Journal of Cardiology</i> , 2014, 30, S442-S454.	1.7	14
61	Changes in Cardiopulmonary Reserve and Peripheral Arterial Function Concomitantly with Subclinical Inflammation and Oxidative Stress in Patients with Heart Failure with Preserved Ejection Fraction. <i>International Journal of Vascular Medicine</i> , 2014, 2014, 1-8.	1.0	14
62	Sirolimus Immunoprophylaxis and Renal Histological Changes in Long-Term Cardiac Transplant Recipients. <i>Annals of Pharmacotherapy</i> , 2014, 48, 837-846.	1.9	5
63	Evaluation of the right ventricle: Comparison of gated blood-pool single photon electron computed tomography and echocardiography with cardiac magnetic resonance. <i>International Journal of Cardiology</i> , 2014, 171, 1-8.	1.7	11
64	Prognostic Value of the Physical Examination in Patients With Heart Failure and Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2014, 2, 15-23.	4.1	29
65	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization. <i>Canadian Journal of Cardiology</i> , 2014, 30, 249-263.	1.7	44
66	TCT-792 Severe Left Ventricular Dysfunction Predicts Mortality In Patients With Symptomatic Functional Mitral Regurgitation Undergoing Percutaneous Edge-To-Edge Repair. <i>Journal of the American College of Cardiology</i> , 2014, 64, B232.	2.8	0
67	Challenge of Informing Patient Decision Making: What Can We Tell Patients Considering Long-Term Mechanical Circulatory Support About Outcomes, Daily Life, and End-of-Life Issues?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 179-187.	2.2	14
68	Long-term evolution, secular trends, and risk factors of renal dysfunction following cardiac transplantation. <i>Transplant International</i> , 2014, 27, 824-837.	1.6	17
69	MitraClip Intervention as Rescue Therapy in Cardiogenic Shock: One-Year Follow-up. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1108.e15-1108.e16.	1.7	13
70	Circulating levels of linoleic acid and HDL-cholesterol are major determinants of 4-hydroxynonenal protein adducts in patients with heart failure. <i>Redox Biology</i> , 2014, 2, 148-155.	9.0	23
71	Should Eligibility for Heart Transplantation Be a Requirement for Left Ventricular Assist Device Use? Recommendations Based on a Systematic Review. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1712-1720.	1.7	7
72	Cardiac remodeling with rhythm versus rate control strategies for atrial fibrillation in patients with heart failure: Insights from the AF-CHF echocardiographic sub-study. <i>International Journal of Cardiology</i> , 2013, 165, 430-436.	1.7	13

#	ARTICLE	IF	CITATIONS
73	The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure. <i>Canadian Journal of Cardiology</i> , 2013, 29, 168-181.	1.7	176
74	Prognostic Value of the Physical Examination in Patients with Heart Failure and Atrial Fibrillation: Insights from the AF-CHF Trial. <i>Journal of Cardiac Failure</i> , 2013, 19, S34.	1.7	0
75	An unusual case of giant cell myocarditis missed in a Heartmate-2 left ventricle apical-wedge section: a case report and review of the literature. <i>Journal of Cardiothoracic Surgery</i> , 2013, 8, 12.	1.1	5
76	Cardiac Resynchronization Therapy in Patients With Heart Failure and a QRS Complex <120 Milliseconds. <i>Circulation</i> , 2013, 127, 873-881.	1.6	132
77	Response to Letter Regarding Article, "Left Ventricular Versus Simultaneous Biventricular Pacing in Patients With Heart Failure and a QRS Complex >120 Milliseconds". <i>Circulation</i> , 2012, 126, .	1.6	0
78	Effects of an aerobic and resistance training program on functional capacity and glucose regulation in patients with heart failure and diabetes. <i>Cardiovascular Endocrinology</i> , 2012, 1, 43-48.	0.8	0
79	Mineralocorticoid Receptor Antagonists and Cardiovascular Mortality in Patients With Atrial Fibrillation and Left Ventricular Dysfunction. <i>Circulation: Heart Failure</i> , 2012, 5, 586-593.	3.9	15
80	Differences in Biomarkers in Patients With Heart Failure With a Reduced vs a Preserved Left Ventricular Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2012, 28, 62-68.	1.7	24
81	Hemodynamic and Clinical Benefits Associated With Chronic Sildenafil Therapy in Advanced Heart Failure: Experience of the Montréal Heart Institute. <i>Canadian Journal of Cardiology</i> , 2012, 28, 69-73.	1.7	16
82	PRKCB is associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 336-343.	1.5	10
83	Severity at Entry to Specialized Heart Failure Clinics: Discrepancies Between Health-Related Quality of Life and Function in Men and Women. <i>Canadian Journal of Cardiology</i> , 2011, 27, 382-387.	1.7	10
84	Eosinophilic Endomyocarditis: An Unusual Cause of Heart Failure in a Young Patient. <i>Canadian Journal of Cardiology</i> , 2011, 27, 390.e15-390.e16.	1.7	1
85	Evaluation of Resynchronization Therapy for Heart Failure in Patients With a QRS Duration Greater Than 120 ms (GREATER-EARTH) Trial: Rationale, Design, and Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2011, 27, 779-786.	1.7	16
86	The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care. <i>Canadian Journal of Cardiology</i> , 2011, 27, 319-338.	1.7	139
87	Outcomes for Women and Men Who Attend a Heart Failure Clinic: Results of a 12-Month Longitudinal Study. <i>Journal of Cardiac Failure</i> , 2011, 17, 540-546.	1.7	11
88	Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 326-331.	0.6	19
89	Description and Assessment of a Common Reference Method for Fluoroscopic and Transesophageal Echocardiographic Localization and Guidance of Mitral Periprosthetic Transcatheter Leak Reduction. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 107-114.	2.9	15
90	Left Ventricular Versus Simultaneous Biventricular Pacing in Patients With Heart Failure and a QRS Complex ≥120 Milliseconds. <i>Circulation</i> , 2011, 124, 2874-2881.	1.6	129

#	ARTICLE	IF	CITATIONS
91	Cardiac masses: an integrative approach using echocardiography and other imaging modalities. <i>Heart</i> , 2011, 97, 1101-1109.	2.9	62
92	Beneficial Effects of Atorvastatin on Lung Structural Remodeling and Function in Ischemic Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 679-688.	1.7	20
93	Patient assessment for cardiac resynchronization therapy: Past, present and future of imaging techniques. <i>Canadian Journal of Cardiology</i> , 2010, 26, 27-34.	1.7	14
94	The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. <i>Canadian Journal of Cardiology</i> , 2010, 26, 185-202.	1.7	125
95	Reviewing the future of renin-angiotensin system blockade: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation. <i>Canadian Journal of Cardiology</i> , 2010, 26, 21E-23E.	1.7	8
96	Mitral annular reduction with subablative therapeutic ultrasound: pre-clinical evaluation of the ReCor device. <i>EuroIntervention</i> , 2010, 6, 54-62.	3.2	25
97	Coronary artery noninvasive imaging in adult Kawasaki disease. <i>Clinical Imaging</i> , 2009, 33, 181-187.	1.5	15
98	Identifying relative cut-off scores with neural networks for interpretation of the minnesota living with heart failure questionnaire. , 2009, 2009, 6242-6.		45
99	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. <i>Canadian Journal of Cardiology</i> , 2009, 25, 85-105.	1.7	79
100	Factors related to time to admission to specialized multidisciplinary clinics in patients with congestive heart failure. <i>Canadian Journal of Cardiology</i> , 2009, 25, e347-e352.	1.7	11
101	Role of Transesophageal Echocardiography in Percutaneous Aortic Valve Replacement with the CoreValve Revalving System. <i>Echocardiography</i> , 2008, 25, 840-848.	0.9	37
102	Percent Predicted Value for the 6-Minute Walk Test: Using Norm-Referenced Equations to Characterize Severity in Persons With CHF. <i>Journal of Cardiac Failure</i> , 2008, 14, 75-81.	1.7	21
103	CYP3A5*1/*3 Genetic Polymorphism Is Associated with Post Cardiac Transplant Renal Dysfunction in Patients Treated with Calcineurin Inhibitors. <i>Journal of Cardiac Failure</i> , 2008, 14, S3.	1.7	1
104	Differences in Concentrations and Correlations amongst Biomarkers of Neurohormonal Activation, Inflammation and Extracellular Matrix Turnover in Patients with HF and a Reduced or a Preserved Left Ventricular Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2008, 14, S38.	1.7	0
105	Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. <i>New England Journal of Medicine</i> , 2008, 358, 2667-2677.	27.0	1,421
106	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure “ 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. <i>Canadian Journal of Cardiology</i> , 2008, 24, 21-40.	1.7	93
107	Temporal variations in hematocrit values in patients with left ventricular dysfunction: Relationship with cause-specific mortality and morbidity and optimal monitoring “ further insights from SOLVD. <i>Canadian Journal of Cardiology</i> , 2008, 24, 45-48.	1.7	6
108	Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: Insights from the Canadian Trial of Atrial Fibrillation (CTAF). <i>Canadian Journal of Cardiology</i> , 2008, 24, 709-713.	1.7	20

#	ARTICLE	IF	CITATIONS
109	Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan. <i>Annals of Pharmacotherapy</i> , 2008, 42, 925-932.	1.9	33
110	Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. <i>Cardiovascular Research</i> , 2008, 79, 405-415.	3.8	44
111	Update on the use of Trandolapril in the management of cardiovascular disorders. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 1147-1158.	2.3	4
112	Long-Term Trandolapril Treatment Is Associated With Reduced Aortic Stiffness. <i>Hypertension</i> , 2007, 49, 1271-1277.	2.7	102
113	Lack of Long-Term Benefits of a 6-Month Heart Failure Disease Management Program. <i>Journal of Cardiac Failure</i> , 2007, 13, 287-293.	1.7	25
114	Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. <i>Canadian Journal of Cardiology</i> , 2007, 23, 21-45.	1.7	131
115	Are there sex-related differences in specialized, multidisciplinary congestive heart failure clinics?. <i>Canadian Journal of Cardiology</i> , 2007, 23, 451-455.	1.7	19
116	Heart rate recovery "a potential marker of clinical outcomes in heart failure patients receiving beta-blocker therapy. <i>Canadian Journal of Cardiology</i> , 2007, 23, 1135-1138.	1.7	19
117	Effects of Combined Candesartan and ACE Inhibitors on BNP, Markers of Inflammation and Oxidative Stress, and Glucose Regulation in Patients With Symptomatic Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 86-94.	1.7	42
118	Percutaneous mitral valve annuloplasty for ischemic mitral regurgitation: First in man experience with a temporary implant. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 1053-1061.	1.7	64
119	Novel therapeutic aspects of percutaneous aortic valve replacement with the 21F CoreValve Revalvingâ„¢ System. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 610-616.	1.7	53
120	Surgical aspects of endovascular retrograde implantation of the aortic CoreValve bioprosthesis in high-risk older patients with severe symptomatic aortic stenosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 134, 1150-1156.	0.8	58
121	Erythropoietin (Epo) Secreting Mesenchymal Stromal Cells and Autocrine Signalling Via the Epo Receptor. A Novel, Cell-Based Paracrine Epo Delivery System for Cardiovascular Therapy.. <i>Blood</i> , 2007, 110, 1198-1198.	1.4	0
122	Noninvasive assessment of coronary artery disease in diabetic patients: The role of stress echocardiography. <i>Canadian Journal of Cardiology</i> , 2006, 22, 26A-33A.	1.7	3
123	Dynamic Quantitative Echocardiographic Evaluation of Mitral Regurgitation in the Operating Department. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 140-146.	2.8	56
124	Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1997-2004.	2.8	507
125	Temporal Increases in Subclinical Levels of Inflammation Are Associated With Adverse Clinical Outcomes in Patients With Left Ventricular Dysfunction. <i>Journal of Cardiac Failure</i> , 2006, 12, 353-359.	1.7	11
126	Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction. <i>American Heart Journal</i> , 2006, 152, 705-712.	2.7	60

#	ARTICLE	IF	CITATIONS
127	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2006, 152, 86-92.	2.7	275
128	Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. <i>Clinical Science</i> , 2006, 110, 483-489.	4.3	84
129	Late iatrogenic coronary stenosis after selective intraoperative antegrade myocardial protection for stentless aortic valve replacement. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 132, 420-421.	0.8	5
130	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2006, 152, 86-92.	2.7	74
131	Inhibition of the Renin-Angiotensin System and Atrial Fibrillation in Heart Failure. <i>Cardiology</i> , 2005, 5, 214-219.	0.3	2
132	Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. <i>Cmaj</i> , 2005, 173, 40-45.	2.0	142
133	Angiotensin Receptor Blockade and Exercise Capacity in Adults With Systemic Right Ventricles. <i>Circulation</i> , 2005, 112, 2411-2416.	1.6	208
134	Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure. <i>American Heart Journal</i> , 2005, 149, 938.e1-938.e7.	2.7	14
135	Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril. <i>American Heart Journal</i> , 2005, 150, 985.e1-985.e8.	2.7	3
136	Reduced atrial fibrillation incidence by angiotensin-converting enzyme inhibitors: A possible contributing mechanism: Reply. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1144.	2.8	0
137	Do statins prevent heart failure in patients after myocardial infarction?. <i>Current Heart Failure Reports</i> , 2004, 1, 156-160.	3.3	2
138	Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2004, 44, 159-164.	2.8	167
139	Hemodynamic responses and neurohormonal activation in "responders" vs. "non-responders" to triple neurohormonal blockade in congestive heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, S35.	1.7	0
140	Heart rate recovery correlates with peak oxygen consumption in heart failure patients referred for cardiopulmonary exercise testing. <i>Journal of Cardiac Failure</i> , 2004, 10, S37.	1.7	0
141	The impact of serum digoxin concentration and enalapril therapy in patients with CHF: the SOLVD trial revisited. <i>Journal of Cardiac Failure</i> , 2004, 10, S88-S89.	1.7	0
142	Retrospective longitudinal cohort study comparing the effects of angiotensin-converting enzyme inhibitors and long-acting calcium channel blockers on total and cardiovascular mortality in patients with hypertension. <i>Clinical Therapeutics</i> , 2004, 26, 1073-1083.	2.5	4
143	Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). <i>American Journal of Cardiology</i> , 2003, 92, 548-553.	1.6	22
144	Effects of angiotensin-converting enzyme inhibition on transient ischemia. <i>Journal of the American College of Cardiology</i> , 2003, 42, 2049-2059.	2.8	42

#	ARTICLE	IF	CITATIONS
145	Decreased heart rate recovery after exercise in patients with congestive heart failure: Effect of β -blocker therapy. <i>Journal of Cardiac Failure</i> , 2003, 9, 296-302.	1.7	63
146	Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. <i>Journal of Molecular and Cellular Cardiology</i> , 2003, 35, 685-694.	1.9	135
147	Cloth tears in asymptomatic survivors of aortic valve replacement with starr-edwards prostheses: detection by transesophageal echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2003, 16, 355-359.	2.8	2
148	Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure. <i>Circulation</i> , 2003, 107, 1291-1296.	1.6	230
149	Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction. <i>Circulation</i> , 2003, 107, 2926-2931.	1.6	549
150	Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H1031-H1041.	3.2	219
151	Therapeutic potential of angiotensin II receptor antagonists. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 1687-1701.	4.1	13
152	Cardiac-directed overexpression of wild-type β _{1B} -adrenergic receptor induces dilated cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 281, H931-H938.	3.2	51
153	Electrophysiological characterization of murine myocardial ischemia and infarction. <i>Basic Research in Cardiology</i> , 2001, 96, 237-250.	5.9	66
154	Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. <i>Journal of Clinical Investigation</i> , 2000, 106, 55-62.	8.2	724
155	Matrix Metalloproteinase Inhibition Attenuates Early Left Ventricular Enlargement After Experimental Myocardial Infarction in Mice. <i>Circulation</i> , 1999, 99, 3063-3070.	1.6	431
156	Transvenous Catheter Ice Mapping and Cryoablation of the Atrioventricular Node in Dogs. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1999, 22, 1488-1498.	1.2	132
157	Comparison of nitroglycerin lingual spray and sublingual tablet on time of onset and duration of brachial artery vasodilation in normal subjects. <i>American Journal of Cardiology</i> , 1999, 84, 952-954.	1.6	60
158	Characterization of the natural history of cervical heterotopic heart transplantation with echocardiography. <i>Journal of Heart and Lung Transplantation</i> , 1999, 18, 510-516.	0.6	6
159	Severe aortic regurgitation immediately after mitral valve annuloplasty. <i>Annals of Thoracic Surgery</i> , 1999, 67, 1487-1489.	1.3	23
160	Decreased submaximal exercise tolerance and increased sympathetic activation in response to cold exposure in patients with congestive heart failure. <i>Journal of Cardiac Failure</i> , 1999, 5, 5.	1.7	1